ISE:MSTY1

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Mainstay Medical International

Executive Summary

Mainstay Medical International plc, together with its subsidiaries, operates as a medical device company in Ireland, the United States, Australia, Germany, and the Netherlands.


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has Mainstay Medical International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MSTY1 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

MSTY1

0%

IE Medical Equipment

0%

IE Market


1 Year Return

-29.8%

MSTY1

0%

IE Medical Equipment

0%

IE Market

Return vs Industry: MSTY1 underperformed the Irish Medical Equipment industry which returned 20.9% over the past year.

Return vs Market: MSTY1 underperformed the Irish Market which returned 5.3% over the past year.


Shareholder returns

MSTY1IndustryMarket
7 Day0%0%0%
30 Day0%0%0%
90 Dayn/a0%0%
1 Year-29.8%-29.8%0%0%0%0%
3 Year-83.0%-83.0%0%0%0%0%
5 Year-81.9%-81.9%0%0%0%0%

Price Volatility Vs. Market

How volatile is Mainstay Medical International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Mainstay Medical International undervalued compared to its fair value and its price relative to the market?

898.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MSTY1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MSTY1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MSTY1 is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: MSTY1 is unprofitable, so we can't compare its PE Ratio to the Irish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MSTY1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MSTY1 is overvalued based on its PB Ratio (898.6x) compared to the XE Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Mainstay Medical International forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-2.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MSTY1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MSTY1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MSTY1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MSTY1's revenue (114.1% per year) is forecast to grow faster than the Irish market (6.3% per year).

High Growth Revenue: MSTY1's revenue (114.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MSTY1's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Mainstay Medical International performed over the past 5 years?

5.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MSTY1 is currently unprofitable.

Growing Profit Margin: MSTY1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MSTY1 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.2% per year.

Accelerating Growth: Unable to compare MSTY1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MSTY1 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.8%).


Return on Equity

High ROE: MSTY1 has a negative Return on Equity (-67833.33%), as it is currently unprofitable.


Next Steps

Financial Health

How is Mainstay Medical International's financial position?


Financial Position Analysis

Short Term Liabilities: MSTY1's short term assets ($20.2M) exceed its short term liabilities ($6.0M).

Long Term Liabilities: MSTY1's short term assets ($20.2M) exceed its long term liabilities ($14.6M).


Debt to Equity History and Analysis

Debt Level: MSTY1's debt to equity ratio (52742.4%) is considered high.

Reducing Debt: Insufficient data to determine if MSTY1's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MSTY1 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MSTY1 has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 17.5% each year.


Next Steps

Dividend

What is Mainstay Medical International's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MSTY1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MSTY1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MSTY1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MSTY1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MSTY1's dividend in 3 years as they are not forecast to pay a notable one for the Irish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average board tenure


CEO

Jason Hannon (47yo)

2.67yrs

Tenure

US$823,207

Compensation

Mr. Jason Marshall Hannon, Esq. & M.A, is Independent Non-Executive Director at Sequana Medical NV since May 23, 2019. He served as an Independent Non-Executive Director of Kuros Biosciences AG since June  ...


CEO Compensation Analysis

Compensation vs Market: Jason's total compensation ($USD823.21K) is above average for companies of similar size in the Irish market ($USD325.59K).

Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Jason Hannon
CEO & Director2.67yrsUS$823.21k0.22% $58.6k
Antoine Papiernik-Berkhauer
Non-Executive Director6.17yrsno datano data
Gregory Garfield
Non-Executive Director4yrsno data0.022% $5.7k
Oern Stuge
Independent Non-Executive Chairmanno dataUS$103.91kno data
David Brabazon
Independent Non-Executive Director6.17yrsUS$58.17k1.59% $415.5k
James Reinstein
Independent Non-Executive Director5yrsUS$58.17kno data
Danny Sachs
Non-Executive Director6.17yrsno data3.84% $1.0m

5.6yrs

Average Tenure

54yo

Average Age

Experienced Board: MSTY1's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 53%.


Top Shareholders

Company Information

Mainstay Medical International plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mainstay Medical International plc
  • Ticker: MSTY1
  • Exchange: ISE
  • Founded: 2008
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €26.206m
  • Shares outstanding: 13.44m
  • Website: https://www.mainstay-medical.com/en

Number of Employees


Location

  • Mainstay Medical International plc
  • 77 Sir John Rogerson’s Quay
  • Block C
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MSTY1ISE (Irish Stock Exchange)YesNew Ordinary SharesIEEURApr 2014
MSTYENXTPA (Euronext Paris)YesNew Ordinary SharesFREURApr 2014
MSTYPBATS-CHIXE (BATS 'Chi-X Europe')YesNew Ordinary SharesGBEURApr 2014
0QUDLSE (London Stock Exchange)YesNew Ordinary SharesGBEURApr 2014

Biography

Mainstay Medical International plc, together with its subsidiaries, operates as a medical device company in Ireland, the United States, Australia, Germany, and the Netherlands. It focuses on commercializing ReActiv8, an implantable restorative neurostimulation system to treat people with disabling chronic low back pain. The company was formerly known as Mainstay Medical plc and changed its name to Mainstay Medical International plc in March 2014. Mainstay Medical International plc was founded in 2008 and is headquartered in Dublin, Ireland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 23:42
End of Day Share Price2020/05/21 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.